Type
Recombinant
Description
IGF-BPscontrolthedistribution,functionandactivityofIGFsinvariouscelltissuesandbodyfluids.IGF-BP6,whichspecificallyinhibitsIGF-IIactions,isproducedbybonecellsandisthemajorIGF-BPpresentincerebrospinalfluid.IGF-BP6hasbeenshowntoinhibitIGF-II-dependentcancerssuchasneuroblastoma,coloncancerandrhaBDomyosarcoma.RecombinantHumanIGF-BP6hasacalculatedmassof22.3 kDaandconsistsof213 aminoacidresidues,includingtheIGF-BPdomainandthyroglobulintype-I domain.RecombinantHumanIGF-BP6migratesatanapparentmolecularweightofapproximately23.0–30.0 kDabySDS-PAGEanalysisundernon-reducingconditions.
AminoAcidSequence
RCPGCGQGVQAGCPGGCVEEEDGGSPAEGCAEAEGCLRREGQECGVYTPNCAPGLQCHPPKDDEAPLRALLLGRGRCLPARAPAVAEENPKESKPQAGTARPQDVNRRDQQRNPGTSTTPSQPNSAGVQDTEMGPCRRHLDSVLQQLQTEVYRGAQTLYVPNCDHRGFYRKRQCRSSQGQRRGPCWCVDRMGKSLPGSPDGNGSSSCPTGSSG
Source
(BTI-Tn-5B1-4)Hi-5Insectcells*
Purity
95%
BIOLOGicalActivity
DeterminedbyitsABIlitytoinhibitIGF-IIinducedproliferationofhumanMCF-7 cells.TheexpectedED50 forthiseffectis0.1–0.4 µg/ml.
Endotoxin
Endotoxinlevelis<0.1 ng/μgofprotein(<1EU/μg).
Reconstitution
Centrifugethevialpriortoopening.Reconstituteinwatertoaconcentrationof0.1–1.0 mg/ml.Donotvortex.Forextendedstorage,itisrecommendedtofurtherdiluteinabuffercontainingacarrierprotein(example0.1%BSA)andstoreinworkingaliquotsat –20°Cto –80°C.
Storage/Expiration
–20°C
